Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 8 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Evaluating agreement between individual nutrition randomised controlled trials and cohort studies - a meta-epidemiological study.BMC medicine · 2025Pooled it
- Selenium, antioxidants, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.The American journal of clinical nutrition · 2020Pooled it
- Selenium exposure and the risk of type 2 diabetes: a systematic review and meta-analysis.European journal of epidemiology · 2018Pooled it
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Selenium supplementation and the risk of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Endocrine · 2014Pooled it
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2014Pooled it
- Guideline
- Selenium supplementation for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2013Pooled it
- Methyl selenocysteine: single-dose pharmacokinetics in men.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- Mendelian Randomization Analysis Reveals Iron as a Potential Contributor to Male Infertility.The world journal of men's health · 2026Article
- Innovative approaches for lung cancer screening and interception.Nature reviews. Clinical oncology · 2026Review
- Associations between Plasma Metal Concentrations and Mortality Risk in Non-Small-Cell Lung Cancer Patients: A Prospective Cohort Study.Biological trace element research · 2026Article
- Soil selenium and oesophageal cancer incidence in China: a large ecological study of population-based cancer registry data.International journal of health geographics · 2026Article
- Selenium compounds for cancer prevention and therapy - human clinical trial considerations.Medical review (2021) · 2025Review
- Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2024Review
- Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy.Journal of personalized medicine · 2024Review
- The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion.Research square · 2024Article
- Selenium in Prostate Cancer: Prevention, Progression, and Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Theranostic applications of selenium nanomedicines against lung cancer.Journal of nanobiotechnology · 2023Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeSelenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. PATIENTS AND
methodsPatients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200 μg versus placebo daily for 48 months. Participation was 6 to 36 months postoperatively and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evidence of recurrence.
resultsThe first interim analysis in October 2009, with 46% of the projected end points accumulated, showed a trend in favor of the placebo group with a low likelihood that the trial would become positive; thus, the study was stopped. One thousand seven hundred seventy-two participants were enrolled, with 1,561 patients randomly assigned. Analysis was updated in June 2011 with the maturation of 54% of the planned end points. Two hundred fifty-two SPTs (from 224 patients) developed, of which 98 (from 97 patients) were lung cancer (38.9%). Lung and overall SPT incidence were 1.62 and 3.54 per 100 person-years, respectively, for selenium versus 1.30 and 3.39 per 100 person-years, respectively, for placebo (P = .294). Five-year disease-free survival was 74.4% for selenium recipients versus 79.6% for placebo recipients. Grade 1 to 2 toxicity occurred in 31% of selenium recipients and 26% of placebo recipients, and grade ≥ 3 toxicity occurred in less than 2% of selenium recipients versus 3% of placebo recipients. Compliance was excellent. No increase in diabetes mellitus or skin cancer was detected.
conclusionSelenium was safe but conferred no benefit over placebo in the prevention of SPT in patients with resected NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.